Survival in patients with myelofibrosis (MF), median overall survival (OS) of 6 to 7 years, is shorter than that of the general population.1 MF is also associated with profound negative effects on quality of life.
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study / Guglielmelli P.; Ghirardi A.; Carobbio A.; Masciulli A.; Maccari C.; Mora B.; Rumi E.; Triguero A.; Finazzi M.C.; Pettersson H.; Paoli C.; Mannelli F.; Vanni D.; Rambaldi A.; Passamonti F.; Alvarez-Larran A.; Andreasson B.; Vannucchi A.M.; Barbui T.. - In: BLOOD ADVANCES. - ISSN 2473-9529. - ELETTRONICO. - 6:(2022), pp. 373-375. [10.1182/bloodadvances.2021006006]
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study
Guglielmelli P.;Ghirardi A.;Maccari C.;Paoli C.;Mannelli F.;Vannucchi A. M.;
2022
Abstract
Survival in patients with myelofibrosis (MF), median overall survival (OS) of 6 to 7 years, is shorter than that of the general population.1 MF is also associated with profound negative effects on quality of life.
| File | Dimensione | Formato | |
|---|---|---|---|
|
advancesADV2021006006 (1).pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
621.88 kB
Formato
Adobe PDF
|
621.88 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
